Cargando…

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B

BACKGROUND: Emerging evidence suggests a pivotal role for B-cell responses in the natural history of chronic hepatitis B. Serum levels of antibodies to hepatitis B core antigen (anti-HBc) vary across infection stages, but their role in predicting response to antiviral therapy is uncertain. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brakenhoff, Sylvia M, de Knegt, Robert J, Oliveira, Jeffrey, van der Eijk, Annemiek A, van Vuuren, Anneke J, Hansen, Bettina E, Janssen, Harry L A, de Man, Robert A, Boonstra, André, Sonneveld, Milan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796168/ https://www.ncbi.nlm.nih.gov/pubmed/35599306 http://dx.doi.org/10.1093/infdis/jiac210

Ejemplares similares

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss
por: Brakenhoff, Sylvia M., et al.
Publicado: (2020)

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B
por: van Campenhout, Margo J. H., et al.
Publicado: (2020)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study
por: Sonneveld, Milan J, et al.
Publicado: (2020)

Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response
por: Sonneveld, Milan J., et al.
Publicado: (2013)

Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B
por: Katwaroe, Warshan K., et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
por: van Kleef, Laurens A., et al.
Publicado: (2021)

Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients
por: Chen, Lu, et al.
Publicado: (2020)

Epidemiology and management of hepatitis B and C in primary care in the Netherlands: data from the Rijnmond Primary Care database
por: Brakenhoff, Sylvia M, et al.
Publicado: (2022)

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment
por: van Campenhout, Margo J.H., et al.
Publicado: (2018)

Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study
por: Beudeker, Boris J. B., et al.
Publicado: (2020)

Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels
por: Zeng, Qing-Lei, et al.
Publicado: (2020)

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin
por: Fevery, Bart, et al.
Publicado: (2016)

Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients
por: Montanari, Noé R, et al.
Publicado: (2020)

Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
por: Sonneveld, Milan J., et al.
Publicado: (2019)

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin
por: Howe, John A., et al.
Publicado: (2014)

Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States
por: Koning, Ludi, et al.
Publicado: (2015)

Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen
por: Rico Montanari, Noe, et al.
Publicado: (2021)

Dynamics of the Immune Response in Acute Hepatitis B Infection
por: Stelma, Femke, et al.
Publicado: (2017)

ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection
por: Maan, Raoel, et al.
Publicado: (2015)

Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment
por: Wang, Kaifa, et al.
Publicado: (2020)

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
por: Lok, Anna S., et al.
Publicado: (2019)

The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030
por: van Dijk, Marleen, et al.
Publicado: (2021)

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis
por: Sonneveld, Milan J., et al.
Publicado: (2020)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C
por: Isfordink, Cas J, et al.
Publicado: (2020)

Negative Regulation of Hepatitis C Virus Specific Immunity Is Highly Heterogeneous and Modulated by Pegylated Interferon-Alpha/Ribavirin Therapy
por: Claassen, Mark A. A., et al.
Publicado: (2012)

Delays in Hepatitis B Immunization Series Completion in People With Human Immunodeficiency Virus
por: Sheikh, Daanish, et al.
Publicado: (2023)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy
por: Chen, Shao-Long, et al.
Publicado: (2023)

Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, Malawi( )
por: Stockdale, Alexander J, et al.
Publicado: (2021)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001–2012
por: Moore, Miranda S, et al.
Publicado: (2018)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir
por: Cruchet, Romuald, et al.
Publicado: (2020)

Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection
por: Krassenburg, Lisette A P, et al.
Publicado: (2020)

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
por: Liem, Kin Seng, et al.
Publicado: (2019)

Hepatitis E Virus Shows More Genomic Alterations in Cell Culture than In Vivo
por: Sari, Gulce, et al.
Publicado: (2019)

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
por: Marcellin, Patrick, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_csm4iq0jr7mdb0nv74qom6q1l7